Northerner
Admin (Retired)
- Relationship to Diabetes
- Type 1
Sernova Corp. (SVA), a clinical stage company developing cell therapy technologies for the long-term treatment of chronic debilitating metabolic diseases including diabetes and hemophilia, today provides a corporate update, summarizing advances made in the clinical development of its Cell Pouch(TM) over the past 12 months and the application of its technologies to new disease indications.
Cell Pouch(TM) Clinical Initiatives
The clinical assessment of the Cell Pouch(TM) in brittle diabetic patients with hypoglycemia unawareness who have received an islet transplant has shown in a small cohort of patients in interim analysis that the Cell Pouch(TM) is biocompatible and safe following implant and transplant. Safety is the primary endpoint of the study.
http://www.marketwatch.com/story/sernova-provides-corporate-update-2014-11-10
Cell Pouch(TM) Clinical Initiatives
The clinical assessment of the Cell Pouch(TM) in brittle diabetic patients with hypoglycemia unawareness who have received an islet transplant has shown in a small cohort of patients in interim analysis that the Cell Pouch(TM) is biocompatible and safe following implant and transplant. Safety is the primary endpoint of the study.
http://www.marketwatch.com/story/sernova-provides-corporate-update-2014-11-10